In conclusion, this meta-analysis of randomized trials of SGLT2 inhibitors in patients with heart failure shows no interaction between the beneficial effect of dapagliflozin and empagliflozin on cardiovascular mortality, all-cause mortality and HF hospitalization, and BMI-defined classes of obesity. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.